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Background: RAS-RAF-MEK-ERK and PI3K-AKT pathways form a significant cascade for potential molecular target
therapy in advanced cancer. The clinical significance of mutations in these genes in advanced gastric cancer (AGC)
is uncertain.
Methods: We collected formalin-fixed, paraffin-embedded and fresh frozen tumor samples from AGC patients
and analyzed the KRAS, NRAS, BRAF and PIK3CA mutations by direct-sequencing. We retrospectively investigated
the clinicopathological features of these mutations in AGC patients, and selected patients with metastatic gastric
cancer.
Results: Among 167 AGC patients, mutations of KRAS codons 12/13 (N = 8/164, 4.9%), PIK3CA (N = 9/163, 5.5%),
and NRAS codon 12/13(N = 3/159, 1.9%) were detected. Comparison of the clinicopathological features of the
mutated KRAS, PIK3CA, NRAS genes with an all-wild type of these genes showed that the frequency of the intestinal
type was significantly higher in patients whose tumor tissue contained KRAS mutations (P = 0.014). Among 125 patients
with metastatic gastric cancer, patients with NRAS codon 12/13 mutations in their tumors had shorter overall survival
compared with NRAS wild-type patients (MST: 14.7 vs 8.8 months, P = 0.011). By multivariate analyses, NRAS codon
12/13 mutation was an indicator for poor prognosis in patients with metastatic gastric cancer (adjusted HR
5.607, 95% CI: 1.637-19.203).
Conclusions: Our study indicated that mutations of KRAS, PIK3CA and NRAS were rare in AGC. NRAS mutations
were likely to associate with poor prognosis in metastatic state of AGC patients, but further validation of other
research is required.Background
Gastric cancer is the second leading cause of cancer
death worldwide with approximately 989,600 new cases
and 738,000 deaths per year, accounting for about 8 per-
cent of new cancers [1]. The highest incidence rates are
in Eastern Asia, the Andean regions of South America,
and Eastern Europe, while the lowest rates are in North
America, Northern Europe, and most countries in Africa
and South Eastern Asia.
Owing to development of systemic chemotherapy, the
survival time for advanced gastric cancer (AGC) has* Correspondence: naoki19800623@gmail.com
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unless otherwise stated.been improved during the past decade. A fluoropyrimidine
and platinum regimen is a standard first-line chemother-
apy in HER2-negative metastatic gastric cancer (mGC)
patients, and trastuzumab added to XP is a standard
chemotherapy in HER2-positive mGC patients in Japan
[2-5]. Although some AGC patients obtained clinical
benefit of systemic chemotherapy, most of the patients
did not attain a clinically satisfactory outcome. Novel
treatment of mGC with more effective and less toxic
chemotherapy regimens was required.
Phase III trials of molecular therapy with mTOR inhibitor,
anti-VEGF antibody, anti-EGFR antibodies were reported in
AGC or gastro-esophageal cancer, but these drugs could not
be demonstrated to have significant efficacy [6,7]. Recently,
ramcirumab, anti-VEGFR target monoclonal antibody, wasral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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mGC patients. It would be a significant therapeutic advan-
tage to identify effective biomarkers in order to match the
responsive cancer cells with the appropriate molecular target
drug and elucidate further mechanisms associated with the
resistance to chemotherapy.
The mitogen-activated protein kinase (MAPK) is part
of a significant intracellular signal pathway that regulates
diverse cellular functions including cell proliferation, cell
cycle regulation, cell survival, angiogenesis, and cell mi-
gration [8]. The Ras proteins were initially identified as
the transforming components of oncogenic viruses, whereas
NRAS was identified as the transforming component of a
neuroblastoma. Ras mutations are found in up to 30% of all
cancers and are particularly common in pancreatic and
colon cancers. Raf is recruited to the cell membrane through
binding to Ras and is activated in a complex process involv-
ing phosphorylation and multiple cofactors. BRAF muta-
tions have a narrow distribution, but are prevalent in a few
specific malignancies such as melanoma, papillary thyroid
cancer, and low-grade ovarian cancer [9-11]. The import-
ance of phosphoinositide 3-kinase (PI3Ks) in cancer was
confirmed by the discovery that the PIK3CA gene, encoding
the PI3K catalytic subunit p110α, is frequently mutated in
some of the most common human tumors [12]. These gen-
etic alterations of PIK3CA consist exclusively of somatic
missense mutations clustered in two “hotspot” regions in
exons 9 and 20, corresponding to the helical and kinase do-
mains of p110α, respectively [13].
Recently, the use of KRAS, BRAF, PIK3CA and NRAS
as biomarkers for molecular target therapy in solid tu-
mors has been widely discussed. Several small-scale bio-
marker analyses of KRAS, BRAF and PIK3CA mutations
were reported previously in AGC [14-16]. The clinical
significance of these mutations in AGC patients is not
already clarified, and further investigations of these
intracellular molecular changes are required.
In the present study, we conducted a genomic analysis
of KRAS, BRAF, PIK3CA and NRAS mutations in orderPatients with advanced gastric cancer who were included 
Patients with metastatic/recurrent gastric cancer who rece
(Group B)
Patinets who underwent surgical resection
Stage I to III patients who had no recurrence  
Stage I to III patients who had recurrence  (N=
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Transfer to another hospitals before systemic 
Exclusion: tumor tissue samples were insuffi
Direct-sequence method of KRAS, NRAS, BRAF and PIK3C
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Figure 1 Diagram of this study.to investigate the clinicopathological features and prog-
nostic role of gene mutations in AGC patients.
Methods
Patients and sample collection
All the data were extracted from the database of our de-
partment, and chart review was done for each patient in
order to obtain important information. We collected tis-
sue samples for analysis of the gene mutation status of
KRAS, BRAF, PIK3CA and NRAS. Tissue samples con-
sisted of samples used in previous biomarker research in
our institution [2,17] and of fresh frozen tissue samples,
which were obtained from previous surgical resections
of AGC in our institution. Tumor tissue samples of 173
AGC patients were gathered, but insufficient samples
from 6 patients were excluded. Finally, we used 167 tis-
sue samples from AGC patients and investigated gene
mutations of KRAS, BRAF, PIK3CA and NRAS by the
direct-sequencing method (whole cohort ). Among 167
AGC patients, 42 patients underwent surgical resection
without systemic chemotherapy (non-metastatic cohort
as group A) and 125 patients with metastatic gastric can-
cer received systemic chemotherapy (metastatic cohort as
group B). A diagram of the present study is shown in
Figure 1. Informed consent of using patient’s tumor
tissues was confirmed from all of the patients who par-
ticipated in the study, which was conducted with the
approval of the Institutional Ethical Review Board of
the National Cancer Center in accordance with the
Helsinki declaration of 1975 (as revised in 1983).
Genomic analyses of KRAS, BRAF, PIK3CA and NRAS
DNA samples were extracted from formalin-fixed, paraffin-
embedded (FFPE) and fresh frozen tumor tissue sections.
Tumor cell-rich areas in the hematoxylin and eosin section
were marked under a microscope, and tissue was scratched
from the area of another deparaffinized unstained section.
DNA from pieces of the scratched tissue sample was iso-
lated using the QIAamp DNA FFPE Tissue Kit (QIAGENin previous biomarker research in our hospital  (N=173) 
ived systemic chemotherapy   (N=125)





cient for direct-sequence method (N=6)
A mutations in AGC  (N=167)
Table 1 Results of gene mutations of KRAS, BRAF, PIK3CA
and NRAS in AGC patients
Gene mutations Proportion (%) Insufficient DNA samples
KRAS codon 12 6/164 (3.7) 3/167
KRAS codon 13 2/164 (1.2) 3/167
KRAS codon 61 0/131 (0.0) 36/167
KRAS codon 146 0/137 (0.0) 30/167
BRAF V600E 0/136 (0.0) 31/167
PIK3CA exon 9 8/163 (4.9) 4/167
PIK3CA exon 20 1/163 (0.6) 4/167
NRAS codon 12 1/159 (0.6) 8/167
NRAS codon 13 2/159 (1.3) 8/167
NRAS codon 61 0/135 (0.0) 32/167
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61), exon 4 (codon 146) of KRASgene and exon 15 (codon
600) of BRAF gene and exon 9 (codon 542, 545), exon 20
(codon 1047) of PIK3CAgene and exon 2 (codon 12, 13),
exon 3 (codon 61) of NRAS gene were amplified by PCR
(the GeneAmp PCR System 9700 thermal cycler). The PCR
products were visualized using agarose gel electrophoresis
with ethidium bromide staining and directly sequenced
using an ABI 3130x/ Genetic Analyzer (Life Technologies
Japan (Applied Biosystems), Tokyo, Japan) according to the
manufacturer’s instructions.
Treatment
A total of 125 patients in group B received systemic
chemotherapy. Regimens of first-line chemotherapy
consisted of CP (n = 42, 33.6%), S-1 (n = 39, 31.2%), 5-FU
(n = 10, 24.0%), a combination of 5-FU and methotrexate
(n = 10, 8.0%), Paclitaxel (n = 3, 2.4%) and XP and/or beva-
cizumab (n = 1, 0.8%). Key anti-cancer drugs for AGC in
Japan are fluoropyrimidine (5-FU, S-1, capecitabine), cis-
platin, irinotecan and taxane. During the whole course of
systemic chemotherapy in group B, the proportions of pa-
tients receiving 5-FU, cisplatin, irinotecan and taxane were
85.6% (n = 107/125), 52.8% (n = 66/125), 60.8% (n = 76/
125), 36.0% (n = 45/125), respectively. In addition, 22 pa-
tients (17.6%) received all key anti-cancer drugs, 37 pa-
tients (29.6%) received 3 of the key drugs, 30 patients
(24.0%) received 2 of the key drugs, and 36 patients
(28.8%) received only one of the key anti-cancer drugs.
The schedules and doses of CP, S-1 and 5-FU were based
on the previous reports [17]. Paclitaxel as monotherapy
was repeated three times weekly for 4 weeks and the doce-
taxel as monotherapy was given by intravenous infusion
once every 3 weeks.
Statistical analyses
We evaluated the proportion of each KRAS, BRAF,
PIK3CA and NRAS mutation in whole cohort and the
prognostic values of these mutations, which were ad-
justed variables of patients’ characteristics in terms of
overall survival (OS) in metastatic group B. OS was de-
fined as the interval from initiation of first-line chemo-
therapy to death or last follow up.
We performed statistical analyses by SPSS statistical
software, version 19 (IBM, Tokyo, Japan). Differences in
the distribution of variables were evaluated using the
Fisher exact test or chi-square test, as appropriate. Median
survival time (MST) was estimated by the Kaplan–Meier
method and survival curves were compared by the log-
rank test. All tests were two-sided and a p-value <0.05 was
defined as statistically significant. We estimated hazard ra-
tio (HR) and the corresponding 95% confidence interval
(CI) for OS using univariate and multivariate analyses
by the Cox proportion hazard models. Variables in thisanalysis included age (≥median/<median), gender (male/
female), ECOG PS (0/1-2), histological type of Lauren
classification (intestinal type/diffuse type), number of
metastatic sites (single/multiple).
Results
Direct sequencing of tissue samples in group B deter-
mined the proportion of each of KRAS, BRAF, PIK3CA
and NRAS (Table 1). Mutations of KRAS codon 12 (3.7%,
n = 6/164) and KRAS codon 13 (1.2%, n = 2/164), PIK3CA
exon 9 (4.9%, n = 8/163), PIK3CA exon 20 (0.6%, n = 1/
163) and NRASmutations (1.9%, n = 3/159) were detected.
On the other hand, mutations in KRAS codon 61, KRAS
codon 146, BRAF V600E, and NRAS codon 146 were not
detected. KRAS codon 12 mutations consisted of G12D
(35G > A, n = 4), G12S (34G > A; n = 1) and G12N (34
35GG>AA; n = 1), and codon 13 mutations consisted of
G13S (37G >A; n = 1) and G13V (38 39GC > TT; n = 1).
PIK3CA exon 9 mutations consisted of E542K (1624G >
A; n = 2), E545K (1633G > A; n = 5), and E545D (1635G >
C; n = 1), and exon 20 mutations consisted of H1047R
(3140A >G; n = 1). NRAS mutations consisted of G12S
(34G > A; n = 1) and G13S (37G > A; n = 1). There were 70
patients whose tumor tissue contained all-wild types of
KRAS (exon2, 3, 4), BRAF (exon 15), PIK3CA (exon9, 20)
and NRAS (exon2, 3). Among the AGC patients whose
tumor tissue contained gene mutations, multiple muta-
tions of KRAS codon 13, PIK3CA codon 545 and NRAS
codon 12 were detected in only one case.
The clinicopathological features of each gene mutation
compared with the all-wild type are summarized in Table 2.
The median ages of patients whose tumor tissue contained
mutations of KRAS, PIK3CA and NRAS (54.5, 58.0 and
56.0 years, respectively) were lower than that of patients
containing all-wild types of KRAS, BRAF, PIK3CA and
NRAS (median age, 64.0 years). There was no significant
difference, except for histological type, among variables of
clinicopathological features such as gender, age, ECOG PS
Table 2 Comparison of clinocopathological features by gene mutations status compared with all-wild type in patients
with AGC patients
All wild-type KRAS codon 12/13 PIK3CA exon 9/20 NRAS codon12/13
KRAS, BRAF, NRAS, PIK3CA Mutant type P-value Mutant type P –value Mutant type P-value
Number of patients 70 8 9 3
Median age 64.0 54.5 58.0 56.0
Gender (%)
Male 49 (70.0) 7 (87.5) 0.429 8 (88.9) 0.432 2 (87.5) 1.000
Female 21 (30.0) 1 (12.5) 1 (11.1) 1 (12.5)
ECOG PS (%)
0 38 (54.3) 3 (37.5) 0.466 4 (44.4) 0.727 1 (33.3) 0.476
1≦ 32 (45.7) 5 (62.5) 5 (55.6) 2 (66.7)
Histological type (%)
Intestinal type 20 (28.6) 6 (75.0) 0.014 4 (44.4) 0.443 0 (0.0) 0.556
Diffuse type 50 (71.4) 2 (25.0) 5 (55.6) 3 (100.0)
No. of metastatic site (%)
1 54 (77.1) 8 (100.0) 0.195 8 (88.9) 0.675 3 (100.0) 1.000
2≦ 16 (22.9) 0 (0.0) 1 (11.1) 0 (0.0)
Metastatic lesion (%)
Lymph node 41 (58.6) 3 (37.5) 0.348 6 (66.7) 0.717 2 (66.7) 0.851
Liver 14 (20.0) 3 (37.5) 3 (33.3) 1 (33.3)
Lung 2 (2.9) 1 (12.5) 0 (0.0) 0 (0.0)
Peritoneal dissemination 18 (25.7) 1 (12.5) 1 (11.1) 0 (0.0)
Other 3 (4.3) 0 (0.0) 0 (0.0) 0 (0.0)
Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance status. We described the clinical data of 90 patients, and we excluded the patients
whose tumor tissues had no gene mutations but at least one gene could not be evaluated.
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type patients, the proportions of intestinal type were higher
in patients with KRAS codon 12/13 mutation (p = 0.014).
The histological tumor type in all patients whose
tumor tissue contained NRAS mutations was the dif-
fuse type of adenocarcinoma.
The background characteristics of metastatic gastric
cancer patients are shown in Table 3. Most patients
(98.4%) were ECOG PS 0/1, and only 2 patients (1.6%)
were ECOG PS 2. A total of 71 patients (60.0%) had the
histologically diffuse tumor type, and 50 patients (40.0%)
had the intestinal type of adenocarcinoma. As for the
number of metastatic sites, 30 patients (24.0%) had me-
tastasis to multiple organs, and 95 patients (76.0%) had
metastasis to one organ. Common metastatic sites were
lymph nodes, peritoneum and liver.
The MST in metastatic GC patients was14.1 months
(95% CI: 12.5-15.7 months). Patients whose tumor tissue
contained a NRAS codon 12/13 mutation had a signifi-
cantly shorter OS compared with those carrying the
NRAS wild type (8.8 month vs. 14.7 months, p = 0.011,
log-rank test). On the other hand, there was no signifi-
cant difference in OS between patients with wild type or
mutant type of KRAS codon 12/13 (13.2 vs. 15.2 months,p = 0.775) and PIK3CA exon 9/20 (13.6 vs. 9.4 months,
p = 0.286).
We evaluated the prognostic factors for OS by univari-
ate and multivariate analyses in metastatic group B.
There was no significant difference among variables of
patient background characteristics, but patients with
ECOG PS 1/2 (HR: 1.380, 95% CI: 0.941-2.024) and
multiple metastatic sites (HR: 1.452, 95% CI: 0.956-
2.206) had a tendency to have shorter OS by univariate
analyses. By multivariate analysis, 2 or more metastatic
sites (HR: 1.613, 95% CI: 1.047-2.484) was an inde-
pendent variable in prediction of shorter OS.
HRs and 95% CIs of variables of gene mutations (KRAS
codon 12/13, PIK3CA exon 9/20 and NRAS codon 12/13)
were adjusted by age, gender, ECOG PS, histological type
and metastatic sites. Among these mutations, the NRAS
codon 12/13 mutation was an independent value in pre-
diction of shorter OS by multivariate analysis (adjusted
HR: 5.607, 95% CI: 1.637-19.203).
Discussion and conclusions
Our analysis suggested that mutations of KRAS codon
12/13 and PIK3CA exon 9/20 (codons 542, 545 and
1047) were not observed frequently in AGC patients,
Table 3 Background characteristics of patients with total







Number of patients 167 42 125
Age (median) 64.0 65.0 63.0
Gender (%)
Male 124 (74.3) 29 (69.0) 95 (76.0)
Female 43 (15.7) 13 (31.0) 30 (24.0)
ECOG PS (%)
0 79 (47.3) 33 (78.6) 46 (36.8)
1 86 (51.5) 9 (21.4) 77 (61.6)
2 2 (1.2) 0 (0.0) 2 (1.6)
Histological type (%)
Intestinal type 60 (35.9) 10 (23.8) 50 (40.0)
Diffuse type 107 (64.1) 36 (76.2) 71 (60.0)
T-stage
T1 9 (5.4) 7 (16.7) 2 (1.6)
T2 34 (20.4) 9 (21.4) 25 (20.0)
T3 101 (60.5) 22 (52.4) 79 (63.2)
T4 23 (13.8) 4 (9.5) 19 (15.2)
N-stage
Nx 4 (2.4) 2 (4.8) 2 (1.6)
N0 22 (13.2) 12 (28.6) 10 (8.0)
N1 56 (33.5) 16 (38.1) 40 (32.0)
N2 53 (31.7) 9 (21.4) 44 (35.2)
N3 32 (19.2) 3 (19.2) 29 (23.2)
Metastatic lesion (%)
≦1 135* (80.8) 40* (95.2) 95 (76.0)
2≦ 32 (19.2) 2 (4.8) 30 (24.0)
Metastatic site (%)
Lymph node 92* (55.1) 19* (45.2) 73 (58.4)
Liver 34 (20.3) 2** (4.8) 32 (25.6)
Lung 8 (4.8) 0 (0.0) 8 (6.4)
Peritoneal dissemination 43 (25.7) 3** (7.1) 40 (32.0)
Other 6 (3.6) 0 (0.0) 6 (4.8)
Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance
status. Staging (TNM classification) is diagnosed by Japanese Classification of
Gastric Carcinoma (The 13th Edition) , *including metastasis to regional lymph
nodes. **resectable lesion.
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knowledge, clinicopathological features and prognostic
roles of KRAS codon 61, KRAS codon 146, NRAS codon
12/13 and NRAS codon 61 have not been reported in
AGC patients previously. Mutations in KRAS codon 61,
KRAS codon 146 and NRAS codon 61 were not de-
tected, but NRAS codon 12/13 mutation was detected in
3 of 159 patients (1.9%) in the present study. Interestingly,the intestinal type of adenocarcinoma was found more fre-
quently in patients whose tumor tissue contained KRAS
codon 12/13 mutations and diffuse type of adenocarcin-
oma was observed in all 3 patients whose tumor tissue
contained NRAS codon 12/13 mutations. In addition,
NRAS mutations were likely to be associated with shorter
OS in metastatic GC patients. Oncogenic mutations often
point to the presence of a therapeutic target that might be
amenable to directed therapeutic intervention. Molecular
target therapy of MARK and PI3K-Akt cascades is an at-
tractive strategy in AGC patients.
In advanced gastro-esophageal adenocarcinoma, the
frequency of KRAS codon 12/13 mutations was approxi-
mately 3.4 to 9.4% according to biomarker analyses of
small-size clinical trials of anti-EGFR antibodies treat-
ment [18-20]. Our study indicated that KRAS mutations
were observed in 4.9% of AGC patients, which is similar
to the results of these clinical trials. Several retrospective
analyses have reported on frequencies and clinicopatho-
logical features of KRAS mutations in gastric cancer
[14-16]. According to these reports, the most common
mutation of KRAS codon 12 was G12D, and all muta-
tions of KRAS codon 13 were G13D. Our study also in-
dicated that G12D mutations were the most common
mutations, and we found in 4 of 6 tumor tissue samples
containing the KRAS codon 12 mutations. On the other
hand, the G13D KRAS mutation was not detected in our
study (G13V and G13S), unlike observations in previous
reports. In these previous reports, most of the tumor tis-
sues containing the KRAS codon 12/13 were of the in-
testinal histological type. Zhao W et al. suggested that
there were significant differences in the presence of
KRAS mutations according to tumor site (antrum vs.
non-antrum, p = 0.002) and status of microsatellite in-
stability (MSI) (MSI-high vs. MSI-loss, p = 0.000076). The
frequency of the intestinal type of adenocarcinoma was
significantly higher than that of the diffuse type of adeno-
carcinoma in our study. There was no definite evidence
for a role of KRAS mutations in prediction and prognosis
of success of molecular target therapy in AGC. Recently,
the randomized, multicenter, phase II/III REAL-3 trial,
which tested the addition of panitumumab to a modified
epirubicin, oxaliplatin, and capecitabine (EOC) regimen,
was reported, and a multivariate biomarker analysis of 200
patients indicated that KRAS mutation was a prognostic
factor for OS [7]. In a large-scale clinical trial of treatment
of gastric-esophageal cancer with anti-EGFR antibodies,
KRAS mutations also appeared to have significant prog-
nostic value, but we need to verify this result by further
biomarker analyses of the treatment of molecular therapy
in AGC.
Gene amplifications, deletions and more recently, som-
atic missense mutations in the PIK3CA gene have been re-
ported in several malignancies, including cancers of the
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gastric cancer, previous reports indicated that the fre-
quency of PIK3CA mutations (exons 9 and 20) was 2.5 to
10.6% [12,14,20]. Nine of 168 AGC patients (4.5%) had
PIK3CA mutations in our study, and there was no great
difference compared with previous reports. Some previous
reports suggested a better prognosis for breast cancer pa-
tients with PIK3CA mutations, whereas others suggested
that PIK3CA mutations were associated with a worse
prognosis in colorectal cancer, endometrial cancer and
lung cancer [23-26]. Multivariate analyses of the REAL-3
trial indicated that PIK3CA mutations indicated poor OS
prognosis in the treatment with anti-EGFR antibodies in
gastro-esophageal cancer. Our data suggested that PIK3CA
mutation was not associated with the prognosis in mGC
patients treated with systemic chemotherapy, although this
study was not a large-scale analysis. Clinical trials of mo-
lecular therapy that targets PI3K-AKT-mTOR pathways
have been initiated recently, thus results of biomarker ana-
lyses of these pathways are required.
NRAS mutations have been mainly described in mel-
anoma and leukemia [27,28], but the prognostic signifi-
cance in these malignancies has been unclear. Some
previous reports have suggested an association between
NRAS mutations and a poor prognosis in melanoma and
a poor response to anti-EGFR antibodies in colorectal
cancer [29]. Our study indicated that the frequency of
NRAS mutations (codons 12 and 13) was 1.9% in AGC
and was lower than that seen in other malignancies.
Interestingly, multivariate analyses showed that small
groups of NRAS mutations had poor prognosis in meta-
static gastric cancer patients who received systemic chemo-
therapy in present study. We must consider a probable bias
of small sample size of NRASmutations. On the other hand,
patient’s characteristics of NRAS mutations were younger
and smaller number of metastasis site than all wild-type pa-
tients. There was no significant difference in chemothera-
peutic regimens and number of key drugs between patients
with NRAS mutations and all-wild type patients. Previously,
NRAS mutations have not been investigated routinely as a
prognostic biomarker in clinical trials of AGC. In addition
to having prognostic significance, that NRAS mutations as
well as KRAS, BRAF and PIK3CA mutations would be bet-
ter to be discussed as potential target for molecular therapy
in AGC patients.
The present study has several limitations. First, the
chemotherapeutic regimens in our study were previous
standard regimens in the mid-2000s in Japan. Second,
we could not conclude definitely from the data in our
study alone that NRAS mutations have prognostic sig-
nificance because of the low frequencies of NRAS muta-
tions and the large confidence intervals. Third, there
were some insufficient samples and we needed to unify
the better methods of sample’s preservation.In conclusions, our study indicated that the frequen-
cies of gene mutations of KRAS, BRAF and PIK3CA
were very similar to those observed in previous reports.
NRAS mutations were rare in AGC patients, but may
have a prognostic value in mGC patients who receive
systemic chemotherapy. We hope that our results will
contribute to future molecular therapy of AGC patients.
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